Skip to main content
. 2024 Jan 18;27(2):108947. doi: 10.1016/j.isci.2024.108947

Table 2.

Cell lines treated with ATO or ATRA

Cell line Accession Platform Sample number
ATO treatment

ASPC1 GSE124069 GPL570 1 control, 3 case
PANC1 GSE124069 GPL570 1 control, 3 case
BXPC3 GSE124069 GPL570 1 control, 4 case
MIApaca GSE124069 GPL570 1 control, 4 case
U266 GSE14519 GPL570 2 control, 3 case
MM.1s GSE14519 GPL570 2 control, 3 case
KMS11 GSE14519 GPL570 2 control, 3 case
8226/S GSE14519 GPL570 2 control, 3 case
BEAS-2B GSE33520 GPL6480 4 control, 3 case
Jurkat GSE46909 GPL16311 4 control, 4 case
HepG2 GSE48441 GPL201 3 control, 15 case
HepG2 GSE6907 GPL201 3 control, 3 case
MEC-1 GSE78207 GPL16987 3 control, 3 case
HepG2 GSE8865 GPL201 3 control, 3 case
hESC GSE94521 GPL570 5 control, 5 case
K562 GSE104813 GPL10332 1 control, 1 case
KU-812 GSE104813 GPL10332 1 control, 1 case
MEG-A2 GSE104813 GPL10332 1 control, 1 case

ATRA treatment

HL-60 GSE34726 GPL10558 6 control, 6 case
NB4 GSE23702 GPL6244 3 control, 6 case
HL-60 GSE5007 GPL96 3 control, 3 case